 | • レポートコード：MRC2-11QY08549 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、149ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は希少疾病用医薬品のグローバル市場について調査・分析したレポートです。種類別（腫瘍学、胃腸、肺、神経学、血液学、循環器、代謝障害、内分泌学、感染症、その他）市場規模、用途別（病院薬局、専門薬局、小売薬局、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別希少疾病用医薬品の競争状況、市場シェア ・世界の希少疾病用医薬品市場：種類別市場規模 2015年-2020年（腫瘍学、胃腸、肺、神経学、血液学、循環器、代謝障害、内分泌学、感染症、その他） ・世界の希少疾病用医薬品市場：種類別市場規模予測 2021年-2026年（腫瘍学、胃腸、肺、神経学、血液学、循環器、代謝障害、内分泌学、感染症、その他） ・世界の希少疾病用医薬品市場：用途別市場規模 2015年-2020年（病院薬局、専門薬局、小売薬局、その他） ・世界の希少疾病用医薬品市場：用途別市場規模予測 2021年-2026年（病院薬局、専門薬局、小売薬局、その他） ・北米の希少疾病用医薬品市場分析：米国、カナダ ・ヨーロッパの希少疾病用医薬品市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの希少疾病用医薬品市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の希少疾病用医薬品市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの希少疾病用医薬品市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Novartis AG、Bristol-Myers Squibb Company、Celgene Corporation、F. Hoffmann-La Roche Ltd.、Pfizer, Inc.、Sanofi S.A.、Alexion Pharmaceuticals, Inc.、Eli Lilly and Company、Novo Nordisk A/S、AstraZeneca、Eisai Co., Ltd.、Daiichi Sankyo Company Limited、Bayer AG、GlaxoSmithKline、Merck & Co., Inc.、Johnson & Johnson、Biogen, Inc.、Takeda、Amgen, Inc. ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Orphan Drugs Market
The global Orphan Drugs market size is projected to reach US$ 126520 million by 2026, from US$ 114540 million in 2020, at a CAGR of 9.7%% during 2021-2026.
Global Orphan Drugs Scope and Market Size
Orphan Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Orphan Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Orphan Drugs market is segmented into
Oncology
Gastrointestinal
Pulmonary
Neurology
Hematology
Cardio-vascular
Metabolic disorders
Endocrinology
Infectious diseases
Others
Segment by Application, the Orphan Drugs market is segmented into
Hospital Pharmacies
Speciality Pharmacies
Retail pharmacies
Others
Regional and Country-level Analysis
The Orphan Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Orphan Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Orphan Drugs Market Share Analysis
Orphan Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Orphan Drugs business, the date to enter into the Orphan Drugs market, Orphan Drugs product introduction, recent developments, etc.
The major vendors covered:
Novartis AG
Bristol-Myers Squibb Company
Celgene Corporation
F. Hoffmann-La Roche Ltd.
Pfizer, Inc.
Sanofi S.A.
Alexion Pharmaceuticals, Inc.
Eli Lilly and Company
Novo Nordisk A/S
AstraZeneca
Eisai Co., Ltd.
Daiichi Sankyo Company Limited
Bayer AG
GlaxoSmithKline
Merck & Co., Inc.
Johnson & Johnson
Biogen, Inc.
Takeda
Amgen, Inc.
1 Study Coverage
1.1 Orphan Drugs Product Introduction
1.2 Market Segments
1.3 Key Orphan Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Orphan Drugs Market Size Growth Rate by Type
1.4.2 Oncology
1.4.3 Gastrointestinal
1.4.4 Pulmonary
1.4.5 Neurology
1.4.6 Hematology
1.4.7 Cardio-vascular
1.4.8 Metabolic disorders
1.4.9 Endocrinology
1.4.10 Infectious diseases
1.4.11 Others
1.5 Market by Application
1.5.1 Global Orphan Drugs Market Size Growth Rate by Application
1.5.2 Hospital Pharmacies
1.5.3 Speciality Pharmacies
1.5.4 Retail pharmacies
1.5.5 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Orphan Drugs Market Size, Estimates and Forecasts
2.1.1 Global Orphan Drugs Revenue 2015-2026
2.1.2 Global Orphan Drugs Sales 2015-2026
2.2 Global Orphan Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Orphan Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Orphan Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Orphan Drugs Competitor Landscape by Players
3.1 Orphan Drugs Sales by Manufacturers
3.1.1 Orphan Drugs Sales by Manufacturers (2015-2020)
3.1.2 Orphan Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Orphan Drugs Revenue by Manufacturers
3.2.1 Orphan Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Orphan Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Orphan Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Orphan Drugs Revenue in 2019
3.2.5 Global Orphan Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Orphan Drugs Price by Manufacturers
3.4 Orphan Drugs Manufacturing Base Distribution, Product Types
3.4.1 Orphan Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Orphan Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Orphan Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Orphan Drugs Market Size by Type (2015-2020)
4.1.1 Global Orphan Drugs Sales by Type (2015-2020)
4.1.2 Global Orphan Drugs Revenue by Type (2015-2020)
4.1.3 Orphan Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Orphan Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Orphan Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Orphan Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Orphan Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Orphan Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Orphan Drugs Market Size by Application (2015-2020)
5.1.1 Global Orphan Drugs Sales by Application (2015-2020)
5.1.2 Global Orphan Drugs Revenue by Application (2015-2020)
5.1.3 Orphan Drugs Price by Application (2015-2020)
5.2 Orphan Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Orphan Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Orphan Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Orphan Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Orphan Drugs by Country
6.1.1 North America Orphan Drugs Sales by Country
6.1.2 North America Orphan Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Orphan Drugs Market Facts & Figures by Type
6.3 North America Orphan Drugs Market Facts & Figures by Application
7 Europe
7.1 Europe Orphan Drugs by Country
7.1.1 Europe Orphan Drugs Sales by Country
7.1.2 Europe Orphan Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Orphan Drugs Market Facts & Figures by Type
7.3 Europe Orphan Drugs Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Orphan Drugs by Region
8.1.1 Asia Pacific Orphan Drugs Sales by Region
8.1.2 Asia Pacific Orphan Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Orphan Drugs Market Facts & Figures by Type
8.3 Asia Pacific Orphan Drugs Market Facts & Figures by Application
9 Latin America
9.1 Latin America Orphan Drugs by Country
9.1.1 Latin America Orphan Drugs Sales by Country
9.1.2 Latin America Orphan Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Orphan Drugs Market Facts & Figures by Type
9.3 Central & South America Orphan Drugs Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Orphan Drugs by Country
10.1.1 Middle East and Africa Orphan Drugs Sales by Country
10.1.2 Middle East and Africa Orphan Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Orphan Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Orphan Drugs Market Facts & Figures by Application
11 Company Profiles
11.1 Novartis AG
11.1.1 Novartis AG Corporation Information
11.1.2 Novartis AG Description and Business Overview
11.1.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Novartis AG Orphan Drugs Products Offered
11.1.5 Novartis AG Related Developments
11.2 Bristol-Myers Squibb Company
11.2.1 Bristol-Myers Squibb Company Corporation Information
11.2.2 Bristol-Myers Squibb Company Description and Business Overview
11.2.3 Bristol-Myers Squibb Company Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Bristol-Myers Squibb Company Orphan Drugs Products Offered
11.2.5 Bristol-Myers Squibb Company Related Developments
11.3 Celgene Corporation
11.3.1 Celgene Corporation Corporation Information
11.3.2 Celgene Corporation Description and Business Overview
11.3.3 Celgene Corporation Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Celgene Corporation Orphan Drugs Products Offered
11.3.5 Celgene Corporation Related Developments
11.4 F. Hoffmann-La Roche Ltd.
11.4.1 F. Hoffmann-La Roche Ltd. Corporation Information
11.4.2 F. Hoffmann-La Roche Ltd. Description and Business Overview
11.4.3 F. Hoffmann-La Roche Ltd. Sales, Revenue and Gross Margin (2015-2020)
11.4.4 F. Hoffmann-La Roche Ltd. Orphan Drugs Products Offered
11.4.5 F. Hoffmann-La Roche Ltd. Related Developments
11.5 Pfizer, Inc.
11.5.1 Pfizer, Inc. Corporation Information
11.5.2 Pfizer, Inc. Description and Business Overview
11.5.3 Pfizer, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Pfizer, Inc. Orphan Drugs Products Offered
11.5.5 Pfizer, Inc. Related Developments
11.6 Sanofi S.A.
11.6.1 Sanofi S.A. Corporation Information
11.6.2 Sanofi S.A. Description and Business Overview
11.6.3 Sanofi S.A. Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Sanofi S.A. Orphan Drugs Products Offered
11.6.5 Sanofi S.A. Related Developments
11.7 Alexion Pharmaceuticals, Inc.
11.7.1 Alexion Pharmaceuticals, Inc. Corporation Information
11.7.2 Alexion Pharmaceuticals, Inc. Description and Business Overview
11.7.3 Alexion Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Alexion Pharmaceuticals, Inc. Orphan Drugs Products Offered
11.7.5 Alexion Pharmaceuticals, Inc. Related Developments
11.8 Eli Lilly and Company
11.8.1 Eli Lilly and Company Corporation Information
11.8.2 Eli Lilly and Company Description and Business Overview
11.8.3 Eli Lilly and Company Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Eli Lilly and Company Orphan Drugs Products Offered
11.8.5 Eli Lilly and Company Related Developments
11.9 Novo Nordisk A/S
11.9.1 Novo Nordisk A/S Corporation Information
11.9.2 Novo Nordisk A/S Description and Business Overview
11.9.3 Novo Nordisk A/S Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Novo Nordisk A/S Orphan Drugs Products Offered
11.9.5 Novo Nordisk A/S Related Developments
11.10 AstraZeneca
11.10.1 AstraZeneca Corporation Information
11.10.2 AstraZeneca Description and Business Overview
11.10.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
11.10.4 AstraZeneca Orphan Drugs Products Offered
11.10.5 AstraZeneca Related Developments
11.1 Novartis AG
11.1.1 Novartis AG Corporation Information
11.1.2 Novartis AG Description and Business Overview
11.1.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Novartis AG Orphan Drugs Products Offered
11.1.5 Novartis AG Related Developments
11.12 Daiichi Sankyo Company Limited
11.12.1 Daiichi Sankyo Company Limited Corporation Information
11.12.2 Daiichi Sankyo Company Limited Description and Business Overview
11.12.3 Daiichi Sankyo Company Limited Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Daiichi Sankyo Company Limited Products Offered
11.12.5 Daiichi Sankyo Company Limited Related Developments
11.13 Bayer AG
11.13.1 Bayer AG Corporation Information
11.13.2 Bayer AG Description and Business Overview
11.13.3 Bayer AG Sales, Revenue and Gross Margin (2015-2020)
11.13.4 Bayer AG Products Offered
11.13.5 Bayer AG Related Developments
11.14 GlaxoSmithKline
11.14.1 GlaxoSmithKline Corporation Information
11.14.2 GlaxoSmithKline Description and Business Overview
11.14.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020)
11.14.4 GlaxoSmithKline Products Offered
11.14.5 GlaxoSmithKline Related Developments
11.15 Merck & Co., Inc.
11.15.1 Merck & Co., Inc. Corporation Information
11.15.2 Merck & Co., Inc. Description and Business Overview
11.15.3 Merck & Co., Inc. Sales, Revenue and Gross Margin (2015-2020)
11.15.4 Merck & Co., Inc. Products Offered
11.15.5 Merck & Co., Inc. Related Developments
11.16 Johnson & Johnson
11.16.1 Johnson & Johnson Corporation Information
11.16.2 Johnson & Johnson Description and Business Overview
11.16.3 Johnson & Johnson Sales, Revenue and Gross Margin (2015-2020)
11.16.4 Johnson & Johnson Products Offered
11.16.5 Johnson & Johnson Related Developments
11.17 Biogen, Inc.
11.17.1 Biogen, Inc. Corporation Information
11.17.2 Biogen, Inc. Description and Business Overview
11.17.3 Biogen, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.17.4 Biogen, Inc. Products Offered
11.17.5 Biogen, Inc. Related Developments
11.18 Takeda
11.18.1 Takeda Corporation Information
11.18.2 Takeda Description and Business Overview
11.18.3 Takeda Sales, Revenue and Gross Margin (2015-2020)
11.18.4 Takeda Products Offered
11.18.5 Takeda Related Developments
11.19 Amgen, Inc.
11.19.1 Amgen, Inc. Corporation Information
11.19.2 Amgen, Inc. Description and Business Overview
11.19.3 Amgen, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.19.4 Amgen, Inc. Products Offered
11.19.5 Amgen, Inc. Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Orphan Drugs Market Estimates and Projections by Region
12.1.1 Global Orphan Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Orphan Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Orphan Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Orphan Drugs Sales Forecast (2021-2026)
12.2.2 North America: Orphan Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Orphan Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Orphan Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Orphan Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Orphan Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Orphan Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Orphan Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Orphan Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Orphan Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Orphan Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Orphan Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Orphan Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Orphan Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Orphan Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Orphan Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Orphan Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Orphan Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Orphan Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Orphan Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Orphan Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Orphan Drugs Market Segments
Table 2. Ranking of Global Top Orphan Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Orphan Drugs Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of Oncology
Table 5. Major Manufacturers of Gastrointestinal
Table 6. Major Manufacturers of Pulmonary
Table 7. Major Manufacturers of Neurology
Table 8. Major Manufacturers of Hematology
Table 9. Major Manufacturers of Cardio-vascular
Table 10. Major Manufacturers of Metabolic disorders
Table 11. Major Manufacturers of Endocrinology
Table 12. Major Manufacturers of Infectious diseases
Table 13. Major Manufacturers of Others
Table 14. Global Orphan Drugs Market Size Growth Rate by Application 2020-2026 (K Units)
Table 15. Global Orphan Drugs Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 16. Global Orphan Drugs Sales by Regions 2015-2020 (K Units)
Table 17. Global Orphan Drugs Sales Market Share by Regions (2015-2020)
Table 18. Global Orphan Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 19. Global Orphan Drugs Sales by Manufacturers (2015-2020) (K Units)
Table 20. Global Orphan Drugs Sales Share by Manufacturers (2015-2020)
Table 21. Global Orphan Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 22. Global Orphan Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Orphan Drugs as of 2019)
Table 23. Orphan Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 24. Orphan Drugs Revenue Share by Manufacturers (2015-2020)
Table 25. Key Manufacturers Orphan Drugs Price (2015-2020) (USD/Unit)
Table 26. Orphan Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 27. Manufacturers Orphan Drugs Product Type
Table 28. Date of International Manufacturers Enter into Orphan Drugs Market
Table 29. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 30. Global Orphan Drugs Sales by Type (2015-2020) (K Units)
Table 31. Global Orphan Drugs Sales Share by Type (2015-2020)
Table 32. Global Orphan Drugs Revenue by Type (2015-2020) (US$ Million)
Table 33. Global Orphan Drugs Revenue Share by Type (2015-2020)
Table 34. Orphan Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)
Table 35. Global Orphan Drugs Sales by Application (2015-2020) (K Units)
Table 36. Global Orphan Drugs Sales Share by Application (2015-2020)
Table 37. North America Orphan Drugs Sales by Country (2015-2020) (K Units)
Table 38. North America Orphan Drugs Sales Market Share by Country (2015-2020)
Table 39. North America Orphan Drugs Revenue by Country (2015-2020) (US$ Million)
Table 40. North America Orphan Drugs Revenue Market Share by Country (2015-2020)
Table 41. North America Orphan Drugs Sales by Type (2015-2020) (K Units)
Table 42. North America Orphan Drugs Sales Market Share by Type (2015-2020)
Table 43. North America Orphan Drugs Sales by Application (2015-2020) (K Units)
Table 44. North America Orphan Drugs Sales Market Share by Application (2015-2020)
Table 45. Europe Orphan Drugs Sales by Country (2015-2020) (K Units)
Table 46. Europe Orphan Drugs Sales Market Share by Country (2015-2020)
Table 47. Europe Orphan Drugs Revenue by Country (2015-2020) (US$ Million)
Table 48. Europe Orphan Drugs Revenue Market Share by Country (2015-2020)
Table 49. Europe Orphan Drugs Sales by Type (2015-2020) (K Units)
Table 50. Europe Orphan Drugs Sales Market Share by Type (2015-2020)
Table 51. Europe Orphan Drugs Sales by Application (2015-2020) (K Units)
Table 52. Europe Orphan Drugs Sales Market Share by Application (2015-2020)
Table 53. Asia Pacific Orphan Drugs Sales by Region (2015-2020) (K Units)
Table 54. Asia Pacific Orphan Drugs Sales Market Share by Region (2015-2020)
Table 55. Asia Pacific Orphan Drugs Revenue by Region (2015-2020) (US$ Million)
Table 56. Asia Pacific Orphan Drugs Revenue Market Share by Region (2015-2020)
Table 57. Asia Pacific Orphan Drugs Sales by Type (2015-2020) (K Units)
Table 58. Asia Pacific Orphan Drugs Sales Market Share by Type (2015-2020)
Table 59. Asia Pacific Orphan Drugs Sales by Application (2015-2020) (K Units)
Table 60. Asia Pacific Orphan Drugs Sales Market Share by Application (2015-2020)
Table 61. Latin America Orphan Drugs Sales by Country (2015-2020) (K Units)
Table 62. Latin America Orphan Drugs Sales Market Share by Country (2015-2020)
Table 63. Latin Americaa Orphan Drugs Revenue by Country (2015-2020) (US$ Million)
Table 64. Latin America Orphan Drugs Revenue Market Share by Country (2015-2020)
Table 65. Latin America Orphan Drugs Sales by Type (2015-2020) (K Units)
Table 66. Latin America Orphan Drugs Sales Market Share by Type (2015-2020)
Table 67. Latin America Orphan Drugs Sales by Application (2015-2020) (K Units)
Table 68. Latin America Orphan Drugs Sales Market Share by Application (2015-2020)
Table 69. Middle East and Africa Orphan Drugs Sales by Country (2015-2020) (K Units)
Table 70. Middle East and Africa Orphan Drugs Sales Market Share by Country (2015-2020)
Table 71. Middle East and Africa Orphan Drugs Revenue by Country (2015-2020) (US$ Million)
Table 72. Middle East and Africa Orphan Drugs Revenue Market Share by Country (2015-2020)
Table 73. Middle East and Africa Orphan Drugs Sales by Type (2015-2020) (K Units)
Table 74. Middle East and Africa Orphan Drugs Sales Market Share by Type (2015-2020)
Table 75. Middle East and Africa Orphan Drugs Sales by Application (2015-2020) (K Units)
Table 76. Middle East and Africa Orphan Drugs Sales Market Share by Application (2015-2020)
Table 77. Novartis AG Corporation Information
Table 78. Novartis AG Description and Major Businesses
Table 79. Novartis AG Orphan Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 80. Novartis AG Product
Table 81. Novartis AG Recent Development
Table 82. Bristol-Myers Squibb Company Corporation Information
Table 83. Bristol-Myers Squibb Company Description and Major Businesses
Table 84. Bristol-Myers Squibb Company Orphan Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 85. Bristol-Myers Squibb Company Product
Table 86. Bristol-Myers Squibb Company Recent Development
Table 87. Celgene Corporation Corporation Information
Table 88. Celgene Corporation Description and Major Businesses
Table 89. Celgene Corporation Orphan Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 90. Celgene Corporation Product
Table 91. Celgene Corporation Recent Development
Table 92. F. Hoffmann-La Roche Ltd. Corporation Information
Table 93. F. Hoffmann-La Roche Ltd. Description and Major Businesses
Table 94. F. Hoffmann-La Roche Ltd. Orphan Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 95. F. Hoffmann-La Roche Ltd. Product
Table 96. F. Hoffmann-La Roche Ltd. Recent Development
Table 97. Pfizer, Inc. Corporation Information
Table 98. Pfizer, Inc. Description and Major Businesses
Table 99. Pfizer, Inc. Orphan Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 100. Pfizer, Inc. Product
Table 101. Pfizer, Inc. Recent Development
Table 102. Sanofi S.A. Corporation Information
Table 103. Sanofi S.A. Description and Major Businesses
Table 104. Sanofi S.A. Orphan Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 105. Sanofi S.A. Product
Table 106. Sanofi S.A. Recent Development
Table 107. Alexion Pharmaceuticals, Inc. Corporation Information
Table 108. Alexion Pharmaceuticals, Inc. Description and Major Businesses
Table 109. Alexion Pharmaceuticals, Inc. Orphan Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 110. Alexion Pharmaceuticals, Inc. Product
Table 111. Alexion Pharmaceuticals, Inc. Recent Development
Table 112. Eli Lilly and Company Corporation Information
Table 113. Eli Lilly and Company Description and Major Businesses
Table 114. Eli Lilly and Company Orphan Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 115. Eli Lilly and Company Product
Table 116. Eli Lilly and Company Recent Development
Table 117. Novo Nordisk A/S Corporation Information
Table 118. Novo Nordisk A/S Description and Major Businesses
Table 119. Novo Nordisk A/S Orphan Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 120. Novo Nordisk A/S Product
Table 121. Novo Nordisk A/S Recent Development
Table 122. AstraZeneca Corporation Information
Table 123. AstraZeneca Description and Major Businesses
Table 124. AstraZeneca Orphan Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 125. AstraZeneca Product
Table 126. AstraZeneca Recent Development
Table 127. Eisai Co., Ltd. Corporation Information
Table 128. Eisai Co., Ltd. Description and Major Businesses
Table 129. Eisai Co., Ltd. Orphan Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 130. Eisai Co., Ltd. Product
Table 131. Eisai Co., Ltd. Recent Development
Table 132. Daiichi Sankyo Company Limited Corporation Information
Table 133. Daiichi Sankyo Company Limited Description and Major Businesses
Table 134. Daiichi Sankyo Company Limited Orphan Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 135. Daiichi Sankyo Company Limited Product
Table 136. Daiichi Sankyo Company Limited Recent Development
Table 137. Bayer AG Corporation Information
Table 138. Bayer AG Description and Major Businesses
Table 139. Bayer AG Orphan Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 140. Bayer AG Product
Table 141. Bayer AG Recent Development
Table 142. GlaxoSmithKline Corporation Information
Table 143. GlaxoSmithKline Description and Major Businesses
Table 144. GlaxoSmithKline Orphan Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 145. GlaxoSmithKline Product
Table 146. GlaxoSmithKline Recent Development
Table 147. Merck & Co., Inc. Corporation Information
Table 148. Merck & Co., Inc. Description and Major Businesses
Table 149. Merck & Co., Inc. Orphan Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 150. Merck & Co., Inc. Product
Table 151. Merck & Co., Inc. Recent Development
Table 152. Johnson & Johnson Corporation Information
Table 153. Johnson & Johnson Description and Major Businesses
Table 154. Johnson & Johnson Orphan Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 155. Johnson & Johnson Product
Table 156. Johnson & Johnson Recent Development
Table 157. Biogen, Inc. Corporation Information
Table 158. Biogen, Inc. Description and Major Businesses
Table 159. Biogen, Inc. Orphan Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 160. Biogen, Inc. Product
Table 161. Biogen, Inc. Recent Development
Table 162. Takeda Corporation Information
Table 163. Takeda Description and Major Businesses
Table 164. Takeda Orphan Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 165. Takeda Product
Table 166. Takeda Recent Development
Table 167. Amgen, Inc. Corporation Information
Table 168. Amgen, Inc. Description and Major Businesses
Table 169. Amgen, Inc. Orphan Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 170. Amgen, Inc. Product
Table 171. Amgen, Inc. Recent Development
Table 172. Global Orphan Drugs Sales Forecast by Regions (2021-2026) (K Units)
Table 173. Global Orphan Drugs Sales Market Share Forecast by Regions (2021-2026)
Table 174. Global Orphan Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 175. Global Orphan Drugs Revenue Market Share Forecast by Regions (2021-2026)
Table 176. North America: Orphan Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 177. North America: Orphan Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 178. Europe: Orphan Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 179. Europe: Orphan Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 180. Asia Pacific: Orphan Drugs Sales Forecast by Region (2021-2026) (K Units)
Table 181. Asia Pacific: Orphan Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
Table 182. Latin America: Orphan Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 183. Latin America: Orphan Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 184. Middle East and Africa: Orphan Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 185. Middle East and Africa: Orphan Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 186. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 187. Key Challenges
Table 188. Market Risks
Table 189. Main Points Interviewed from Key Orphan Drugs Players
Table 190. Orphan Drugs Customers List
Table 191. Orphan Drugs Distributors List
Table 192. Research Programs/Design for This Report
Table 193. Key Data Information from Secondary Sources
Table 194. Key Data Information from Primary Sources
List of Figures
Figure 1. Orphan Drugs Product Picture
Figure 2. Global Orphan Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Oncology Product Picture
Figure 4. Gastrointestinal Product Picture
Figure 5. Pulmonary Product Picture
Figure 6. Neurology Product Picture
Figure 7. Hematology Product Picture
Figure 8. Cardio-vascular Product Picture
Figure 9. Metabolic disorders Product Picture
Figure 10. Endocrinology Product Picture
Figure 11. Infectious diseases Product Picture
Figure 12. Others Product Picture
Figure 13. Global Orphan Drugs Sales Market Share by Application in 2020 & 2026
Figure 14. Hospital Pharmacies
Figure 15. Speciality Pharmacies
Figure 16. Retail pharmacies
Figure 17. Others
Figure 18. Orphan Drugs Report Years Considered
Figure 19. Global Orphan Drugs Market Size 2015-2026 (US$ Million)
Figure 20. Global Orphan Drugs Sales 2015-2026 (K Units)
Figure 21. Global Orphan Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 22. Global Orphan Drugs Sales Market Share by Region (2015-2020)
Figure 23. Global Orphan Drugs Sales Market Share by Region in 2019
Figure 24. Global Orphan Drugs Revenue Market Share by Region (2015-2020)
Figure 25. Global Orphan Drugs Revenue Market Share by Region in 2019
Figure 26. Global Orphan Drugs Sales Share by Manufacturer in 2019
Figure 27. The Top 10 and 5 Players Market Share by Orphan Drugs Revenue in 2019
Figure 28. Orphan Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 29. Global Orphan Drugs Sales Market Share by Type (2015-2020)
Figure 30. Global Orphan Drugs Sales Market Share by Type in 2019
Figure 31. Global Orphan Drugs Revenue Market Share by Type (2015-2020)
Figure 32. Global Orphan Drugs Revenue Market Share by Type in 2019
Figure 33. Global Orphan Drugs Market Share by Price Range (2015-2020)
Figure 34. Global Orphan Drugs Sales Market Share by Application (2015-2020)
Figure 35. Global Orphan Drugs Sales Market Share by Application in 2019
Figure 36. Global Orphan Drugs Revenue Market Share by Application (2015-2020)
Figure 37. Global Orphan Drugs Revenue Market Share by Application in 2019
Figure 38. North America Orphan Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 39. North America Orphan Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 40. North America Orphan Drugs Sales Market Share by Country in 2019
Figure 41. North America Orphan Drugs Revenue Market Share by Country in 2019
Figure 42. U.S. Orphan Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 43. U.S. Orphan Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 44. Canada Orphan Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 45. Canada Orphan Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 46. North America Orphan Drugs Market Share by Type in 2019
Figure 47. North America Orphan Drugs Market Share by Application in 2019
Figure 48. Europe Orphan Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 49. Europe Orphan Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 50. Europe Orphan Drugs Sales Market Share by Country in 2019
Figure 51. Europe Orphan Drugs Revenue Market Share by Country in 2019
Figure 52. Germany Orphan Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 53. Germany Orphan Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. France Orphan Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 55. France Orphan Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. U.K. Orphan Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 57. U.K. Orphan Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 58. Italy Orphan Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 59. Italy Orphan Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 60. Russia Orphan Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 61. Russia Orphan Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 62. Europe Orphan Drugs Market Share by Type in 2019
Figure 63. Europe Orphan Drugs Market Share by Application in 2019
Figure 64. Asia Pacific Orphan Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 65. Asia Pacific Orphan Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 66. Asia Pacific Orphan Drugs Sales Market Share by Region in 2019
Figure 67. Asia Pacific Orphan Drugs Revenue Market Share by Region in 2019
Figure 68. China Orphan Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 69. China Orphan Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Japan Orphan Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 71. Japan Orphan Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. South Korea Orphan Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 73. South Korea Orphan Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. India Orphan Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 75. India Orphan Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Australia Orphan Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 77. Australia Orphan Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Taiwan Orphan Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 79. Taiwan Orphan Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Indonesia Orphan Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 81. Indonesia Orphan Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Thailand Orphan Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 83. Thailand Orphan Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 84. Malaysia Orphan Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 85. Malaysia Orphan Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 86. Philippines Orphan Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 87. Philippines Orphan Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 88. Vietnam Orphan Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 89. Vietnam Orphan Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 90. Asia Pacific Orphan Drugs Market Share by Type in 2019
Figure 91. Asia Pacific Orphan Drugs Market Share by Application in 2019
Figure 92. Latin America Orphan Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 93. Latin America Orphan Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 94. Latin America Orphan Drugs Sales Market Share by Country in 2019
Figure 95. Latin America Orphan Drugs Revenue Market Share by Country in 2019
Figure 96. Mexico Orphan Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 97. Mexico Orphan Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 98. Brazil Orphan Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 99. Brazil Orphan Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 100. Argentina Orphan Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 101. Argentina Orphan Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 102. Latin America Orphan Drugs Market Share by Type in 2019
Figure 103. Latin America Orphan Drugs Market Share by Application in 2019
Figure 104. Middle East and Africa Orphan Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 105. Middle East and Africa Orphan Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 106. Middle East and Africa Orphan Drugs Sales Market Share by Country in 2019
Figure 107. Middle East and Africa Orphan Drugs Revenue Market Share by Country in 2019
Figure 108. Turkey Orphan Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 109. Turkey Orphan Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 110. Saudi Arabia Orphan Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 111. Saudi Arabia Orphan Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 112. U.A.E Orphan Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 113. U.A.E Orphan Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 114. Middle East and Africa Orphan Drugs Market Share by Type in 2019
Figure 115. Middle East and Africa Orphan Drugs Market Share by Application in 2019
Figure 116. North America Orphan Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 117. North America Orphan Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Europe Orphan Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 119. Europe Orphan Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 120. Asia Pacific Orphan Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 121. Asia Pacific Orphan Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 122. Latin America Orphan Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 123. Latin America Orphan Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 124. Middle East and Africa Orphan Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 125. Middle East and Africa Orphan Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 126. Porter's Five Forces Analysis
Figure 127. Channels of Distribution
Figure 128. Distributors Profiles
Figure 129. Bottom-up and Top-down Approaches for This Report
Figure 130. Data Triangulation
Figure 131. Key Executives Interviewed
希少性肺疾患治療の世界市場（～2026年） Orphan illnesses are those which are not generally looked into, those where particular medicines are not accessible, and those which may just be of restricted enthusiasm to researchers and specialists. Orphan lung diseases are exemplified by the purported disregarded infectious diseases, which are e…- 希少疾患の世界市場（～2026年） An orphan disease is defined as a condition that affects fewer than 200,000 people nationwide. This includes diseases as familiar as cystic fibrosis, Lou Gehrig's disease, and Tourette's syndrome, and as unfamiliar as Hamburger disease, Job syndrome, and acromegaly, or "gigantism." Some diseases hav…
- 後天性孤児造血疾患治療薬の世界市場（～2026年） Acquired orphan blood disease is a type of rare blood disorder, which occurs due to the presence of insufficient amount of red blood cells in the blood. This disease is characterized by the body’s inability to produce red blood cells. Moreover, improper functioning of bone marrow also leads to lack …
- 後天性孤児血液疾患の世界市場（～2026年） Acquired orphan blood disease is a type of rare blood disorder, which occurs due to the presence of insufficient amount of red blood cells in the blood. This disease is characterized by the body?s inability to produce red blood cells. Moreover, improper functioning of bone marrow also leads to lack …
- 血友病薬の世界市場（～2026年） The hemophilia treatment drugs market is experiencing entry of a large number of new drugs in the market. Few of them have already arrived and other long lasting clotting factors and more promising drugs are on their way to get launched in this market. For instance, follow up data from phase I/II st…